Lapix Therapeutics Inc.

Cambridge, MA · Founded 2019 · CIK 0001947620 · Biotech · Private

Orally bioavailable small molecule therapeutics for immune system restoration

lapix.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$12M
4 Form D · Aug 2025
14 months since last filing
Contracts
—
No federal contracts on record
Patents
23
3 granted · 20 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,247,500
Private capital raisedForm D · SEC$5,947,478
Private capital raisedForm D · SEC$2,219,990
Private capital raisedForm D · SEC$2,200,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1461Cage Bio, Inc.—$19M
1462PridCor Therapeutics, LLC—$6.0M
1463BLUESTEM BIOSCIENCES INC—$5.0M
1464Lapix Therapeutics Inc.—$12M
1465ANDSON BIOTECH INC.—$8.3M
1466GC Therapeutics——
1467Endogenex, Inc.—$122M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Anas FathallahDirector · Executive Officer
  • Anthony GibneyDirector
  • Francisco LeonDirector
  • Henry McKinnellDirector
  • Jason NorrisDirector · Executive Officer

Patents

USPTO · 3 granted of 23

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.